Drug Trial Radar · NCT06305559
A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque
Last checked: Nov 19, 2026Latest source record: Apr 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
May 16, 2024
Primary completion
Nov 2027
Study completion Feb 2028
Sponsor
- Lead sponsor
- NewAmsterdam PharmaIndustry
- Sponsor type
- Industry
- First posted
- Mar 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This placebo-controlled, double-blind, randomized, Phase 3 study is being conducted in adult participants with high-risk atherosclerotic cardiovascular disease (ASCVD) who are not adequately controlled by their maximally tolerated lipid-modifying therapy, to assess the impact of the obicetrapib 10 mg + ezetimibe 10 mg FDC daily on coronary plaque and inflammation characteristics, evaluated using cardiovascular computed tomography angiography (CCTA).
Conditions
- Lipidemia
- Coronary Artery Disease
- Plaque, Atherosclerotic
Interventions
obicetrapib 10 mg + ezetimibe 10 mg FDC dailyDrug
Active treatment
PlaceboOther
Baseline lipid modifying therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- • To evaluate the effect of obicetrapib 10 mg + ezetimibe 10 mg fixed dose combination (FDC) daily on total non-calcified coronary atherosclerotic plaque volume (NCPV) at 18 months.Time frame: 18 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
NGMR
Hialeah, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.